New stimulation pattern may boost leg power in neurological patients
NCT ID NCT06421753
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This completed study tested whether a new type of electrical stimulation, called spatially distributed sequential stimulation, works better than standard stimulation for people with upper motor neuron disease. Ten adults with stable symptoms used both methods while cycling. Researchers measured how much power their leg muscles produced. The goal is to find a more comfortable and effective way to help these patients exercise.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Spatially Distributed Sequential Functional Electrical Stimulation (device)
- What this could lead to
- If it works, this could point toward a more effective way to use electrical stimulation to help people with upper motor neuron disease cycle or exercise.
- What could go wrong
- This is a very small, early study with only 10 participants. The results may not apply to everyone, and the improvement in muscle power might be small or not meaningful in daily life.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
10 people
The number who actually took part.
- Started
-
May 2024
- Finished
-
Dec 2024
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Patients with Upper Motor Neuron syndrome: * adult (\> 18 years) * motor deficit due to an acquired traumatic or neurodegenerative motor deficiency of the central nervous system (MRC\<4/5) * stable clinical condition, particularly on the cardiovascular level (recent assessment by a cardiologist with stress test) * non denervated muscles * tolerant to muscle electrical stimulation * having given written consent * able to cycle 30 minutes with FES-cycling Exclusion Criteria: * major cognitive comprehension disorders that could compromise understanding of the protocol and the smooth running of the study * cardiac pacemaker and other contraindications relating to the use of electrostimulation (in particularly "deep vein thrombosis") * spasticity of the lower limbs making flexion/extension movement difficult * participation in another study * pregnancy * people with the following legal and administrative states or situations: * people placed under judicial protection; * persons deprived of their liberty, persons subject to psychiatric care and persons admitted to a health or social establishment for purposes other than that of clinical investigation; * unemancipated minors; * people who are not affiliated to a social security scheme or beneficiaries of such a scheme
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Upper motor neuron disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
SMR Val Rosay
Saint-Didier-au-Mont-d'Or, France, 69370, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.